Physician profile
Sam Anouna
NPI 1639119365
$5,365.80
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,411 · 2020: $1,192 · 2021: $2,031 · 2022: $701 · 2023: $29.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $29.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $29.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,126.07 | 2019-2023 | Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $468.70 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $414.76 | 2019-2022 | |
| Gilead Sciences, INC. | $327.72 | 2019-2022 | |
| Fujifilm Healthcare Americas Corporation | $219.77 | 2021 | |
| Allergan, INC. | $217.50 | 2020 | |
| Janssen Biotech, INC. | $199.21 | 2019-2022 | |
| Celgene Corporation | $184.31 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $175.21 | 2019-2020 | |
| Redhill Biopharma INC. | $156.89 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $142.79 | 2021-2022 | |
| Qol Medical, LLC | $138.83 | 2019-2021 | |
| Boston Scientific Corporation | $134.18 | 2019-2020 | |
| Braintree Laboratories, INC. | $80.70 | 2019-2021 | |
| Ucb, INC. | $65.39 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $50.16 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $42.93 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $33.59 | 2020-2021 | |
| Shionogi INC | $33.37 | 2020 | |
| Organon LLC | $25.75 | 2021-2022 | |
| Shire North American Group INC | $24.52 | 2019 | |
| Baxter Healthcare | $23.90 | 2022 | |
| Daiichi Sankyo INC. | $18.92 | 2021 | |
| Alfasigma USA, INC. | $17.52 | 2020 | |
| Ferring Pharmaceuticals INC. | $15.53 | 2021 | |
| Dova Pharmaceuticals | $15.41 | 2019 | |
| Alexion Pharmaceuticals, INC. | $12.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Anouna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.